The new findings come from the ongoing RECOVER trial and build on results seen in a 2023 trial.
Common diabetes drug linked to lower rate of long COVID
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- COVID-adapted stewardship intervention linked to reduced antibiotic use, resistance in Chicago hospital
- Evidence growing for COVID antivirals to cut poor outcomes, long COVID, experts say
- Machine-learning monoclonal antibody allocation in pandemic could cut hospital cases by a third
- COVID-infected psychiatric hospital roommates pose high risk of infection, especially in elderly